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ttp://dx.doi.org/10.1016/j.ajpath.2013.06.024Membrane-associated serine protease matriptase is widely expressed by epithelial/carcinoma cells in
which its proteolytic activity is tightly controlled by the Kunitz-type protease inhibitor, hepatocyte
growth factor activator inhibitor (HAI-1). We demonstrate that, although matriptase is not expressed in
lymphoid hyperplasia, roughly half of the non-Hodgkin B-cell lymphomas analyzed express signiﬁcant
amounts of matriptase. Furthermore, a signiﬁcant proportion of these tumors express matriptase in the
absence of HAI-1. Aggressive Burkitt lymphoma was more likely than indolent follicular lymphoma to
express matriptase alone (86% versus 36%). In the absence of signiﬁcant HAI-1 expression, the
lymphoma cells activate and shed active matriptase when the cells are stimulated with mildly acidic buffer
or the hypoxia-mimicking agent, CoCl2. The shed active matriptase can initiate pericellular proteolytic
cascades by activating urokinase-type plasminogen activator on the cell surface of monocytes, and it can
activate prohepatocyte growth factor. In addition, matriptase knockdown suppressed proliferation and
colony-forming ability of neoplastic B cells in culture and growth as tumor xenografts in mice. Further-
more, exogenous expression of HAI-1 signiﬁcantly suppressed proliferation of neoplastic B cells. These
studies suggest that dysregulated pericellular proteolysis as a result of unregulated matriptase expression
with limited HAI-1 may contribute to the pathological characteristics of several human B-cell lymphomas
through modulation of the tumor microenvironment and enhanced tumor growth. (Am J Pathol 2013,
183: 1306e1317; http://dx.doi.org/10.1016/j.ajpath.2013.06.024)Supported by National Cancer Institute (NCI) grant R01 CA 123223
(M.J. and C.-Y.L.), Maryland Cigarette Reconstitute Fund (C.-Y.L.), and
the assistance of the following shared resources at the Lombardi Compre-
hensive Cancer Center, which are supported in part by NIH/NCI grant P30-
CA051008: Tissue Culture Shared Resource, Microscopy and Imaging
Shared Resource, and Histology and Tissue Shared Resource.
Disclosures: C.-Y.L. is an inventor on US patents 6,077,938 and
6,677,377, and M.J. and C.-Y.L. are inventors on US patent 7,355,015 (all
related to matriptase).Pericellular proteolysis plays crucial roles in the modulation
of the tumor microenvironment through activation of cyto-
kines and growth factors, remodeling of the extracellular
matrix (ECM), and release of sequestered growth factors and
cytokines from the ECM.1 Matriptase, a type II trans-
membrane serine protease, has recently been recognized as
an important pericellular protease that may affect tumor
microenvironments through the initiation of a protease
cascade and the activation of growth factors.2e4 Matriptase
and its cognate inhibitor, hepatocyte growth factor (HGF)
activator inhibitor (HAI)-1, are broadly co-expressed in
epithelial tissues,5,6 where critical interactions between the
protease and the inhibitor are required for the maintenance ofstigative Pathology.
.the integrity of the epithelium, epidermal differentiation and
barrier functions, and the development of the placenta.7e9
Both matriptase and HAI-1 are commonly dysregulated in
human tumors of epithelial origin and may contribute to
Matriptase in B-Cell Lymphomathe development and progression of carcinomas.10 Mild
overexpression of matriptase in the absence of a parallel
increase in HAI-1 expression in mouse skin upsets a tightly
regulated balance between these proteins in favor of
increased proteolysis, which results in the spontaneous
development of squamous cell carcinomas and enhances
sensitivity to chemical carcinogens.11 HAI-1, a Kunitz-type
serine protease inhibitor, modulates matriptase proteolytic
activity through the formation of extremely stable complexes
with active matriptase, thereby avoiding undesired proteol-
ysis and the potential toxicity of active matriptase.12,13 The
inhibition of unregulated matriptase activation by HAI-1
appears to be important for the biosynthesis, intracellular
trafﬁcking, and even zymogen activation of matriptase.14,15
Although most matriptase studies have focused on epithe-
lial and carcinoma cells, in which HAI-1 plays a pivotal role in
intracellular trafﬁcking, zymogen activation, and inhibition of
matriptase, growing evidence has shown that altered matrip-
tase expression or regulation may be important in hemato-
logical cells and neoplasms. Matriptase expression has been
detected in THP-1 human monocytic cells, and the protease
was reported to be responsible for accelerating plasmin
generation via activation of urokinase plasminogen activator
(uPA).16Matriptase has also been reported to be expressed by,
and involved in, the activation of peritoneal macrophages
through the activation of macrophage-stimulating protein-1
and the recepteur d’origine nantais.17 Matriptase was also
detected in two Burkitt lymphoma (BL) cells (Daudi and ST
486) in our previous study18 and, more recently, in human
leukemia.19 In contrast to the situation in epithelial/carcinoma
cells, these hematological cells express no or low levels of
HAI-1. Regulation and even function of matriptase in hema-
tological cells and tumors may, therefore, be different from
that in epithelial and carcinoma cells. In the current study, we
set out to investigate the role and regulation of matriptase in
human B-cell lymphomas. Our data show that matriptase is
expressed in a variety of non-Hodgkin B-cell lymphomas
in the absence of, or with limited, HAI-1 expression, with
important implications for tumor behavior.
Materials and Methods
Chemicals and Reagents
Gelatin and cobalt chloride (CoCl2) were purchased from
Sigma-Aldrich (St. Louis, MO); N-tert-butoxycarbonyl-Gln-
Ala-Arg-7-amido-4-methylcoumarin was obtained from Enzo
Life Sciences (Farmingdale, NY); pyro-Glu-Gly-Arg-p-nitro-
aniline hydrochloride (p-NA) for uPA was from Aniara
(HyphenBioMed,WestChester,OH); andhumanpro-uPAwas
purchased from American Diagnostica Inc. (Stamford, CT).
Silver stain plus was obtained from Bio-Rad (Hercules, CA).
Cell Lines and shRNA Knockdown
Hematological and breast cancer cells were obtained from
the Tissue Culture Shared Resource in the LombardiThe American Journal of Pathology - ajp.amjpathol.orgComprehensive Cancer Center, Georgetown University
(Washington, DC). The hematological cells were cultured in
RPMI 1640 medium supplemented with 10% fetal bovine
serum (FBS), 100 U/mL penicillin, and 100 mg/mL strep-
tomycin. The T-47D human breast carcinoma cells were
maintained in Dulbecco’s modiﬁed Eagle’s medium sup-
plemented with 10% FBS. All cells were maintained at
37C in a humidiﬁed atmosphere with 5% CO2. The human
BL cells Raji and diffuse large B-cell lymphoma (DLBCL)
cells SU-DHL-4 were used to establish stable matriptase
knockdown pools. The cells were transduced with lentiviral
vectors expressing either a nontargeting control shRNA
sequence (NT) or shRNAs targeting the human matriptase
gene (ST14) (Open Biosystems, Lafayette, CO). The shRNA
targeting sequences were as follows: NT, 50-CCGGCAA-
CAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTT-
CATCTTGTTGTTTTT-30; MTP 1, 50-CCGGCGTGTCCA-
GAAGGTCTTCAATCTCGAGATTGAAGACCTTCTG-
GACACGTTTTTG-30; and MTP 2, 50-CCGGCAATGA-
CTTCACCTTCGACTACTCGAGTAGTCGAAGGTGA-
AGTCATTGTTTTTG-30. Transduced cells were selected
with 1 mg/mL puromycin, and stable pools of resistant cells
were established. Knockdown of matriptase expression was
conﬁrmed by using Western blot analysis. The doxycycline-
inducible HAI-1eexpressing cell line was generated using
a Lenti-X Tet-On 3G inducible expression system from
Clontech Laboratories, Inc. (Mountain View, CA). Brieﬂy,
the open reading frame of the HAI-1 gene (SPINT-1) was
generated by PCR ampliﬁcation and ligated into the pLVX-
TER-IRES expression vector, along with the puromycin-
resistant marker. This lentiviral expression vector was
stably transduced into a preselected neomycin-resistant BL
Raji line that stably expressed Tet-On 3Getransactivated
regulator proteins. Transduced cells were selected in the
presence of 1 mg/mL puromycin, and stable pools of resistant
cells were established. Cell pools derived from this dual
selection process were then selected on the basis of induction
of HAI-1 expression in the presence of 2 mg/mL tetracycline
analogue, doxycycline. Cell extracts of stable clones were
analyzed by using Western blot analysis with M19 mono-
clonal antibody (mAb).
IHC Data
The study was reviewed and approved as being of minimal
to no risk by the Institutional Review Board at the
University of Maryland, School of Medicine (Baltimore),
and the University of Texas MD Anderson Cancer Center
(Houston). Lymphoma tissue and nonneoplastic lymph node
specimens were obtained from the University of Maryland
Greenebaum Cancer Center Pathology Biorepository and
Research Core and the MD Anderson Cancer Center Tumor
Bank. Immunohistochemistry (IHC) was performed
following a standard protocol provided by the reagent
manufacturer (Dako, Carpinteria, CA), as described in our
previous studies.20,21 The staining results were blinded and1307
Chou et alindependently scored by two experienced hematopatholo-
gists (X.F.Z. and K.H.Y.), according to published scaled
scoring criteria.22 Both membranous and focal cytoplasmic
staining patterns were considered positive. A score was
assigned to each specimen according to both a scaled crite-
rion (the proportion of cells positive for staining) and staining
intensity. The scaled criteria were as follows: 0, <25%
neoplastic cells stained; 1þ, 26% to 50% neoplastic cells
stained; 2þ, 50% to 75% neoplastic cells stained; and 3þ,
>75% neoplastic cells stained. The lymphoma staining
intensities were divided into negative, weak, and strong
staining patterns. Because the staining intensity score might
vary from assay to assay, our scaled criteria overrule the
staining intensity if only a few lymphoma cells showed
strong staining. Occasional interobserver inconsistencies
were reconciled by rereview by the two hematopathologists
together to reach agreement. In combination, the lymphomas
were roughly divided into negative (0 and/or negative), low
(1þ and/or weak), and high (2þ, 3þ, and strong) expresser
groups. Weak staining and 1þ positivity were considered
a low level of expression, whereas strong staining and 2þ or
greater were considered a high level or strong expression.
Cleavage of Protein Substrates
Samples of single-chain pro-HGF or pro-uPA were incu-
bated with puriﬁed active matriptase in 100 mmol/L Tris-
HCl, pH 8.5, at 37C for the indicated times. Incubation was
stopped by adding SDS sample buffer containing dithio-
threitol to the reactions and boiling the resultant mixture.
The cleavage products were separated by SDS-PAGE and
analyzed by using Western blot analysis for HGF or by
silver staining for uPA.
Matriptase Activity Assay
For gelatin zymography, 1mg/mL gelatin was copolymerized
in 7.5% SDS polyacrylamide gels. The details of the gelatin
zymography assay can be found in our previous study.23 For
ﬂuorogenic peptide substrate assays, 125 nmol/L of N-tert-
butoxycarbonyl-Gln-Ala-Arg-amido-4-methylcoumarin was
mixed with the matriptase samples in a reaction buffer con-
taining 100mmol/L Tris-HCl, pH 8.5, and 100 mg/mL bovine
serum albumin in a total volume of 200 mL. The increase in
ﬂuorescence resulting from hydrolysis of the peptide
substrates was recorded using a DTX 880multimode detector
(Beckman Coulter, Fullerton, CA), with an excitation wave-
length of 360 nm and a detection emission of 480 nm.
uPA Activation on the Cell Surface of U937 Cells
The U937 monocytes were washed to remove any uPA
present on the cell surface, as described previously.16,24
Brieﬂy, the cells were washed twice in RPMI 1640
medium supplemented with 25 mmol/L HEPES, pH 7.4, and
then treated with 50 mmol/L glycine-hydrochloride buffer,1308pH 3.0, containing 0.1 mmol/L sodium chloride for 5
minutes, followed by neutralization with 0.5 mmol/L HEPES
buffer, pH 7.5, containing 0.1 mmol/L sodium chloride. The
cells were then washed once with RPMI 1640 medium sup-
plemented with 25 mmol/L HEPES, pH 7.4, and resuspended
at a density of 1  107 cells/mL. The cells were incubated
with 1.4 nmol/L pro-uPA for 20 minutes at 37C, after which
the unbound pro-uPA was washed away with RPMI 1640
medium supplemented with 25 mmol/L HEPES, pH 7.4.
Cells were incubated at a ﬁnal density of 1 106 cells/mL in
0.05 mmol/L Tris-HCl, pH 7.4, 0.1 mmol/L NaCl, 0.01%
Tween-80 in the presence of the chromogenic substrate,
pyro-Glu-Gly-Arg-p-NA, and active matriptase at 37C. The
amidolytic activity of uPA was measured against the chro-
mogenic substrate, and the rate at which p-NA was released
was measured photometrically at 405 nm on a DTX 880
multimode detector.
In Vitro Cell Proliferation Assay
An equal number of cells were plated in complete growth
media, and the cells were maintained at 37C in 5% CO2 for
4 days. Aliquots were taken from the wells every 24 hours,
mixed with trypan blue (Invitrogen, Grand Island, NY) at
a 1:1 ratio to identify viable cells, which were then counted
using a hemocytometer and a microscope.
Clonogenic Assay
The clonogenic assay was conducted using a modiﬁed
version of the protocol provided by R&D Systems, Inc.,
Minneapolis, MN. Brieﬂy, 5  103 cells were plated in
quadruplicate in 0.5 mL of plating medium consisting of
1.2% methylcellulose, 10% FBS, and 200 mmol/L L-gluta-
mine in Iscove’s modiﬁed Dulbecco’s medium (Invitrogen).
The plates were maintained at 37C in 5% CO2 for 10 days,
when they were stained with 1 mg/mL iodonitrotetrazolium.
Colonies consisting of >50 cells were automatically coun-
ted and analyzed using a colony counter.
Xenograft Tumors
Animal experiments were conducted under a protocol
approved by the Georgetown University Animal Care and
Use Committee. Before injection into animals, the cells were
tested and conﬁrmed to be negative for mycoplasma using
a mycoplasma detection kit (Lonza, Basel, Switzerland).
Eight-week-old female severe combined immunodeﬁcient
(SCID) mice (Taconic Farms, Inc., Hudson, NY) were
divided into three groups (NT, 1, and 2; nZ 10) and injected
into the ﬂank s.c. with 107 cells in 0.1 mL of medium. Tumor
volume was determined by measuring the length, width, and
height of tumors and calculating their product. The mice were
euthanized as a cohort 24 days after tumor inoculation, and
the tumors were removed and weighed. The resected tumors
were ﬁxed in 10% neutral-buffered formalin, embedded inajp.amjpathol.org - The American Journal of Pathology
Figure 1 Expression of matriptase and HAI-1
in human lymphoma cells. Cell lysates prepared
from 21 hematological cancer cells and T-47D
breast cancer cells, as indicated, were analyzed by
immunoblot for matriptase using mAb M24 and
HAI-1 using mAb M19.
Matriptase in B-Cell Lymphomaparafﬁn, and divided into sections for histological analysis.
The IHC staining for matriptase was performed as previously
described, modiﬁed to include the use of M.O.M blocking
reagent (Vector Labs, Burlingame, CA) to suppress back-
ground staining of endogenous mouse immunoglobulin. For
histopathological examination, sections were stained with
H&E. The levels of proliferation and apoptosis were assessed
separately by staining sections with a mouse antibody against
the proliferation marker, Ki-67 (Leica Biosystems, Buffalo
Grove, IL), and for apoptosis using the ApopTag Plus system
(Millipore, Billerica, MA).
Statistical Analysis
The data were analyzed using the Student’s t-test for two
samples assuming equal variances. P < 0.05 was considered
signiﬁcant.
Results
Human Hematological Malignancies Express Matriptase
in the Absence of Signiﬁcant HAI-1 Expression
To understand the pathophysiological role of matriptase and
HAI-1 in the context of human hematological cells and their
cancers, we ﬁrst analyzed their protein expression levels by
using Western blot analysis in a panel of 21 lymphoma and
leukemia cell lines (Figure 1). The T47-D breast cancer cells
were used as a representative control for the ratio of
matriptase/HAI-1 typically seen in epithelial cells (Figure 1).
Previous data have demonstrated almost complete concor-
dance of expression of matriptase and HAI-1 in a variety of
human epithelial and carcinoma cell lines.17,25 Surprisingly,
we observed that the expression of matriptase and HAI-1 was
almost mutually exclusive in the 21 hematopoietic cell lines
tested (Figure 1). Matriptase was found to be expressed at
high levels in four BL lines, all three DLBCL lines, one
(SUP-T1) of six T-cell leukemia lines, and THP-1 mono-
cytes. Among these nine cell lines, HAI-1 was eitherThe American Journal of Pathology - ajp.amjpathol.orgundetectable or only detected or at low levels. The highest
expression of HAI-1 was found in acute lymphoblastic
leukemia-derived REH cells; high expression of HAI-1 was
also found in the T-cell leukemia line, CCRF-HSB-2, and the
T-cell lymphoma line, HuT-78. None of the four HAI-
1eexpressing cells expressed matriptase. These data
demonstrate that some B-cell lymphoma lines, including BL
and DLBCL, express matriptase in the context of low HAI-1
expression, in stark contrast to the large HAI-1/matriptase
ratio commonly found in epithelial and carcinoma cells.
Matriptase Expression Is Detected in a Variety of B-Cell
Lymphomas, But Not in Reactive B Cells
We next determined the expression of matriptase and HAI-1
in non-Hodgkin lymphomas (NHLs) by IHC staining of
formalin-ﬁxed, parafﬁn-embedded human tissue specimens.
A total of 65 NHLs were examined, which included 25
follicular lymphomas (FLs), 27 DLBCLs, and 13 BLs. In
addition, three reactive lymph nodes were examined as
nontumor controls. Neither matriptase nor HAI-1 was
detected in the three reactive lymph nodes (Table 1). Of the
25 FLs, 11 (44%) were positive for matriptase and 14 (56%)
were positive for HAI-1. Of the 11 FLs that scored positive
for matriptase, 7 (64%) were positive for HAI-1; 9 (64%) of
the 14 FLs that were scored positive for HAI-1 were posi-
tive for matriptase. Correlation analysis revealed that the
matriptase protein expression level was not correlated with
HAI-1 protein expression levels (Pearson correlation coef-
ﬁcient r Z 0.0141, P Z 0.9467). Representative examples
of matriptase and HAI-1 staining of the reactive lymph
nodes and FLs are shown in Figure 2.
Of the 27 DLBCLs, 12 (44%) were positive for matriptase
and 19 (70%)were positive forHAI-1.Of the 12DLBCLs that
scored positive for matriptase, 9 (75%) were positive for HAI-
1; 9 (47%) of the 19 DLBCLs that were scored positive for
HAI-1 were positive for matriptase. Correlation analysis
revealed thatmatriptase protein expression inDLBCLwas not
correlated with HAI-1 protein expression (Pearson correlation1309
Table 1 Summary of Matriptase and HAI-1 IHC Staining
Variable Case group (no.) MTPþ HAI-1þ (MTPþ, HAI-1)/MTPþ (MTPþ, HAI-1þ)/HAI-1þ
Reactive lymph nodes 3 0/3 (0) 0/3 (0) 0/0 (0) 0/0 (0)
FLs 25 11/25 (44) 14/25 (56) 4/11 (36.4) 9/14 (64.3)
DLBCLs 27 12/27 (44.4) 19/27 (70.4) 3/12 (25.0) 9/19 (47.4)
BLs 13 7/13 (53.8) 5/13 (38.5) 6/7 (85.7) 1/5 (20)
Data are given as number/total number (percentage) unless otherwise indicated.
Chou et alcoefﬁcient r Z 0.08479, P Z 0.6741). Representative
examples of matriptase and HAI-1 staining of DLBCL are
shown in Figure 3.
Of the 13 BLs, 7 (54%) were positive for matriptase and 5
(39%) were positive for HAI-1. Of the 7 BLs that scored
positive for matriptase, 1 (14%) was positive for HAI-1; 1
(20%) of the 5 BLs that were scored positive for HAI-1 was
positive for matriptase. Correlation analysis revealed that
matriptase protein expression in BLs was not correlated with
HAI-1 protein expression (Pearson correlation coefﬁcient
r Z 0.33071, P Z 0.2697). Representative examples of
matriptase and HAI-1 staining of BLs are shown in Figure 3.
In summary, our analysis demonstrates that roughly half
of the NHLs examined express matriptase (30 of 65) andFigure 2 Expression of matriptase and HGF activator inhibitor (HAI)-1
in human reactive lymph nodes and follicular lymphoma. Tissue sections
from three parafﬁn-embedded cases of reactive lymph nodes and 25 cases
of FL were analyzed by IHC for matriptase using mAb M24 and HAI-1 using
mAb M19. Representative staining for matriptase (A, C, and E) and HAI-1
(B, D, and F). Scale bar Z 20 mm.
1310HAI-1 (38 of 65), in contrast to the reactive lymph nodes
that exhibited no staining for either protein. No statistically
signiﬁcant relationship was found between the expression of
matriptase and HAI-1 within the three groups of NHLs.
Matriptase-positive BLs were, however, less likely to
express HAI-1 compared with matriptase-positive FLs
(Fisher’s exact test, P Z 0.0573) or matriptase-positive
DLBCLs (Fisher’s exact test, P Z 0.019).
Expression of Matriptase in the Absence of HAI-1 by
Lymphoma Cells Allows the Shedding of Free Active
Matriptase
The lack of signiﬁcant HAI-1expression in some lymphomas
suggests that these tumor cells may regulate matriptase in
a profoundly different way than that used by epithelial and
carcinoma cells. Some lymphomas express matriptase in the
absence of signiﬁcant HAI-1 expression, raising the possi-
bility that these tumors may produce signiﬁcant amounts of
free active matriptase. Furthermore, this active enzyme may
have a signiﬁcant half-life once liberated from the cells, in
stark contrast to the case in epithelial cell systems and tumors,
where we have shown that activated matriptase has a short
half-life, being almost immediately inactivated by binding to
HAI-1.26 To test this possibility, we induced matriptase
activation in Raji BL cells by transiently exposing the cells to
a phosphate buffer, pH 6.0, for 20 minutes (Figure 4),
a method that we have previously used to stimulate epithelial
and carcinoma cells to robustly activate matriptase.26,27
Activation of matriptase was also induced by incubation of
the BL cells with 200 mmol/L CoCl2 overnight (Figure 4).
The proteins shed into the cell-conditioned buffer (for pH
6.0) and media (for CoCl2) were collected and analyzed for
the presence of active matriptase using multiple assays.
Immunoblot analyses of the shed proteins using a matriptase
mAb revealed that more matriptase was shed from the cells
exposed to the mildly acidic buffer or CoCl2 containing
media compared with those cells exposed to basal media
(Figure 4). When an activated matriptase-speciﬁc mAb was
used, a signiﬁcant amount of active matriptase was present in
the conditioned buffer and media of the acid- or CoCl2-
treated cells, respectively, but not in the controls (Figure 4).
The presence of a matriptase-like proteolytic activity in the
conditioned buffer and media was demonstrated by gelatin
zymography (Figure 4) and by measuring amidolytic activity
with a synthetic ﬂuorogenic substrate commonly used for
matriptase (Figure 4). By using the activated matriptaseajp.amjpathol.org - The American Journal of Pathology
Figure 3 Expression of matriptase and HAI-1 in human DLBCLs and BLs.
Tissue sections from 27 parafﬁn-embedded DLBCL cases and 13 BL cases
were analyzed by IHC for matriptase using mAb M24 and for HAI-1 using
mAb M19. Representative staining for matriptase (A, C, and E) and HAI-1
(B, D, and F). Scale bar Z 20 mm.
Matriptase in B-Cell LymphomamAb, active matriptase was found to be responsible for the
proteolytic activity. The strong gelatinocytic activity detected
at a position consistent with the expected size of active
matriptase (Figure 4) was immunodepleted using the active
matriptase-speciﬁc antibody (Figure 4) and then recovered
using mAb (Figure 4). Similarly, the strong amidolytic
activity (Figure 4) was almost completely depleted by the
activated matriptase mAb (Figure 4). The proteolytic activity
was then eluted and recovered from the mAb (Figure 4).
These data demonstrate that the lack of signiﬁcant levels of
HAI-1 in these cells results in the release of free active
matriptase into the extracellular milieu. Matriptase proteo-
lytic activity was only detected in the conditioned buffer and
media and not in lysates of cells that conditioned the buffer
and media. This suggests that active matriptase is rapidly
shed to the extracellular milieu by the cells and that this
shedding would allow the protease to act close to the cancer
cells and in the proximity of the stromal cells.
Matriptase Activates uPA and HGF
The production and shedding of free active matriptase by B-
cell lymphoma cells might contribute to the malignancy ofThe American Journal of Pathology - ajp.amjpathol.orgthe cells by mediating the activation of other proteases and
growth factors. Among the protease substrates of matriptase,
uPA has received the most attention.2,3,16 In solution, active
matriptase can cleave single-chain pro-uPA into two-chain
uPA in a dose-dependent manner after an 8-hour incuba-
tion. By using a uPA chromogenic substrate, pyro-Glu-Gly-
Arg-p-NA, the activation of pro-uPA was assessed by
increasing amounts of active matriptase (0 to 0.2 nmol/L). At
the top concentration of 0.2 nmol/L, active matriptase does
not cleave the chromogen substrate. Although uPA activation
determined by the proteolytic activity was observed to occur
in a dose-dependent manner, the activation of uPA by active
matriptase appeared to be modest (Figure 5B). Activation of
pro-uPA is known to proceed more rapidly when pro-uPA is
bound to its membrane receptor, urokinase-type plasminogen
activator receptor (uPAR). Incubating both active matriptase
and pro-uPA with human monocytic U937 cells, which can
retain pro-uPA via uPAR and do not express matriptase,
resulted in robust active uPA generation (Figure 5C). The
level of uPA activity resulting from incubation of the pro-
uPA with 0.2 nmol/L active matriptase in the context of
U937 cells was approximately ﬁve times higher than the level
of activity produced by incubating the same amount of pro-
uPA in cell-free solution, containing 0.2 nmol/L active
matriptase during the same time period (approximately 80
minutes) (Figure 5C).
Matriptase has been shown to be able to activate several
growth factors, including HGF, platelet-derived growth
factors C and D, and macrophage-stimulating factor-1,2,4,17
among which pro-HGF is particularly relevant in the context
of DLBCLs.28 Incubation of pro-HGF with subnanomolar
concentrations of active matriptase for 30 minutes rapidly
converted the single-chain pro-HGF into its two-chain form
in a dose-dependent manner, as assessed by the appearance
of the HGF a-chain at the cost of pro-HGF using immu-
noblot analysis (Figure 5D). These data suggest that the free
active matriptase shed by lymphoma cells can modulate the
tumor microenvironment by initiating the proteolytic
cascade and activating growth factors.
Suppression of Matriptase Expression or
Overexpression of HAI-1 Blunts the Proliferation of B-
Cell Lymphoma
To evaluate the contribution of matriptase to the malignant
behavior of B-cell lymphomas, we set out to determine the
effect of suppressing matriptase expression, or HAI-1
overexpression, on the behavior of Raji BL cells, which
express matriptase in the absence of HAI-1, such as other
BL cells. Two shRNA constructs targeting different regions
of the matriptase mRNA were used to generate stable
matriptase-knockdown (MTPKD) pools: MTPKD 1 with
>52% reduction in expression and MTPKD 2 with >88%
reduction in matriptase expression at the protein level, when
compared with that of the NT population or the parental
cells (wild type) (Figure 6A). The reduced expression of1311
Figure 4 Lymphoma cells produce free, active
matriptase. Raji BL cells were induced to activate
matriptase (lanes 2) by exposing cells to 150
mmol/L phosphate buffer, pH 6.0, for 20 minutes or
200 mmol/L CoCl2 in basal medium overnight, or
basal medium as a nonactivation control (lanes 1).
The shed proteins were analyzed by immunoblot for
total matriptase using mAb M24 (MTP) and for
activated matriptase using mAb M69 (activated
MTP). The shed proteins collected from matriptase
activation were immunoprecipitated using the acti-
vated matriptase mAb M69. The total shed protein
(lanes L), unbound (lanes UB), and the proteins
eluted from the M69 antibody (lanes E) were
analyzed for matriptase gelatinolytic activity by
gelatin zymography and by measuring amidolytic
activity against a synthetic ﬂuorescent substrate.
Chou et almatriptase affects the proliferation of the cells, because both
matriptase knockdown cultures grew more slowly than the
nontarget control by 27% for MTPKD 1 and 40% for
MTPKD 2 (Figure 6B). The colony-forming ability of Raji
cells was reduced by >80% in MTPKD 2, but only by
a negligible amount in MTPKD 1 (Figure 6C). This differ-
ence may be attributed to the moderate levels of matriptase
suppression in MTPKD 1. The reduction in proliferation and
clonogenicity associated with strong suppression of matrip-
tase expression was also observed using the DLBCL cell
line, SU-DHL-4. When matriptase expression was almost
completely suppressed by shRNA-mediated knockdown
(Figure 6D), the DLBCL cells proliferated 50% slower than
the control cells (Figure 6E) and lost their ability to form
colonies (Figure 6F). These data suggest that the role of
matriptase in tumor growth is not limited to BLs.
Consistent with the suppression of the proliferation of the
cancer cells by the reduced matriptase expression, increased
HAI-1 expression in Raji cells, mediated through the use ofFigure 5 Activation of pro-uPA and HGF by active matriptase. A: Pro-uPA wa
nmol/L) at 37C for 8 hours. The activation was analyzed by SDS-PAGE, and th
chromogenic substrate were incubated with increasing amounts of active matripta
at 37C. The generation of active uPA was monitored during the course of 80 min
absorbance at 405 nm. D: Pro-HGF was incubated with increasing amounts of puriﬁ
was analyzed by immunoblot for HGF cleavage using an antibody directed agains
1312a doxycycline-induced expression system, also suppresses
the proliferation of the cells (Figure 6, G and H). Signiﬁcant
levels of HAI-1 were induced by doxycycline treatment in
the Raji clone transduced with a lentiviral vector, containing
the HAI-1 cDNA under the control of a tetracycline-
responsive promoter, and a viral vector expressing the
tetracycline transactivator protein (Figure 6G). Negligible
HAI-1 expression was seen in this clone in the absence of
doxycycline. No HAI-1 expression was detected in the
control clone containing only the vector expressing the
tetracycline transactivator, regardless of the presence of
doxycycline. Transduction with the HAI-1einducible con-
struct does not appear to alter cell proliferation in the
absence of doxycycline when compared with the Raji clone
containing tetracycline transactivator alone (Figure 6H).
Although the treatment with doxycycline does slightly alter
the growth of the control clone, the induced HAI-1
expression further suppressed the proliferation of the Raji
cells in a statistically signiﬁcant manner. Collectively, ours incubated with increasing amounts of puriﬁed active matriptase (0 to 2
e protein bands were visualized by silver stain. B and C: Pro-uPA and its
se (0 to 0.2 nmol/L) in solution (B) or with U937 human monocytic cells (C)
utes by measuring the liberation of the chromophore from the substrate by
ed active matriptase (0 to 2 nmol/L) at 37C for 30 minutes. The activation
t the b subunit of HGF.
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Figure 6 Modulation of matriptase and HA-1 expression alters in vitro growth of lymphoma cells. A and D: Cell lysates prepared from the wild-type (WT),
NT, and matriptase knockdown populations of Raji BL cells (1 and 2) and SU-DHL-4 DLBCL cells (2) were analyzed by immunoblot for matriptase using
matriptase mAb M24 and for b-actin as a loading control. B and E: The proliferation rates of the Raji and SU-DHL-4 NT and the matriptase knockdown pools
(1 and 2) were analyzed. The data are presented as means  SD of triplicate determinations. Statistical signiﬁcance was determined by Student’s t-test. C and
F: A total of 5  103 cells of the NT and the matriptase knockdown pools (1 and 2) were grown in methylcellulose for 10 days, and the resultant number of
colonies was counted. The means  SD of triplicate determinations are presented, and statistical signiﬁcance was assessed by Student’s t-test. G: Cell lysates
prepared from the doxycycline-inducible HAI-1 line (HAI-1) and the empty vector line (CRL) were prepared from cells grown in the absence (Dox) or presence
(Doxþ) of doxycycline and analyzed by immunoblot for HAI-1 using mAb M19 and for actin as a loading control. H: The proliferation rates of the doxycycline-
inducible HAI-1 line (HAI-1) and the empty vector line (CRL) were determined in the absence (Control and HAI-1) or presence (Control, Doxþ and HAI-1,
and Doxþ) of doxycycline. The data are presented as means  SD of triplicate determinations. Statistical signiﬁcance was determined by Student’s t-test.
***P < 0.001 (B, C, E, F, and H).
Matriptase in B-Cell Lymphomastudy suggests that the unopposed proteolysis resulting from
the overexpression of matriptase in the absence of signiﬁcant
HAI-1 expression confers an increased growth potential on
lymphoma cells. The impact of matriptase suppression on
tumor growth was further investigated by xenografting the
cells into SCIDmice. The twoMTPKD populations (1 and 2)
and the NT-control (107 cells/0.5 mL) were injected s.c. into
SCID mice. The tumors were measured and the volume was
calculated on the indicated dates (Figure 7A), and the tumors
were harvested and weighed when the animals were eutha-
nized (Figure 7B). The data are presented as the means  SEThe American Journal of Pathology - ajp.amjpathol.orgof nine tumors in the NT, 10 tumors in MTPKD 1, and seven
tumors in MTPKD 2. The sizes and weights of MTPKD 2
tumors were signiﬁcantly smaller than those of MTPKD 1 or
nontarget control tumors (Figure 7, A and B, respectively).
The overall morphological characteristics of the NT control
and MTPKD 2 Raji tumors were similar based on the H&E
staining (Figure 7, C and F, respectively). Both tumors
showed areas of viable cancer cells, particularly around the
periphery, with areas of necrosis, particularly in the center of
the tumors. The differential expression of matriptase in the
NT control and theMTPKD 2 tumors was conﬁrmed by IHC,1313
Figure 7 Suppression of matriptase expression reduces the growth of B-cell lymphoma tumor xenografts. Three Raji pools of the NT and the two
matriptase-knockdown populations (1 and 2) of Raji cells (107 cells in 0.1 mL) were injected s.c. into SCID mice. The growth of tumors was monitored by
measuring their dimensions using calipers and calculating their volume on the indicated dates (A) and assessed by the weight when the animals were
euthanized (B). The data are presented as means  SEM of nine tumors for the NT control, 10 tumors in matriptase-knockdown 1 cells, and seven tumors in the
knockdown 2 cells. Statistical signiﬁcance was determined by Student’s t-test. *P < 0.05, ***P < 0.001. Tumor sections were analyzed by H&E staining for
histological assessment (C and F), by IHC for matriptase (D and G) and Ki-67 (data not shown), and by TUNEL assay for apoptosis (E and H).
Chou et alwith much higher levels in the NT control compared with the
MTPKD 2 tumors (Figure 7, D and G). To explore the
reason(s) behind smaller MTPKD 2 tumor size compared
with the NT control, sections of each tumor type were stained
for a marker of proliferation (Ki-67) and for apoptosis using
the TUNEL assay. The Ki-67 staining was variable in
different portions of the tumors, but when considering the
tumors as a whole, did not appear to be signiﬁcantly different
between the NT control and MTPKD 2 tumors (data not
shown). In contrast, TUNEL staining appeared to demon-
strate that there was a consistently higher level of apoptosis in
the MTPKD 2 tumors compared with the NT control tumors
(Figure 7, E and H), suggesting that the smaller size of the
MTPKD 2 tumors might be the result of increased apoptosis.Discussion
In this study, we have examined the role of matriptase-
mediated pericellular proteolysis in NHLs, and revealed
interesting contrasts between carcinoma andB-cell lymphoma1314with respect to how matriptase activity is dysregulated. First,
matriptase is expressed in a cancer-speciﬁc manner in NHLs,
because the enzyme was detected at signiﬁcant levels in
approximately 50% of the specimens examined, whereas
matriptase is not expressed in reactive B cells. This is in
contrast to the widespread expression of matriptase in both
carcinoma andnormal epithelial cells. Second,HAI-1 does not
play nearly as important a role in matriptase biological char-
acteristics in B-cell lymphomas as it does in epithelial tumors,
where, in addition to rapidly binding to and inactivating active
matriptase, HAI-1 also facilitates the expression and zymogen
activation of the protease.15,29 Expression correlation between
matriptase and HAI-1 in NHL is not signiﬁcant. Furthermore,
in many cases of matriptase-positive FLs and DLBCLs, the
IHC stainingofHAI-1was always relativelyweak and in some
cases did not appear to be localized at the cell surface.
Matriptase is synthesized as a zymogen that has limited
intrinsic enzymatic activity, and undergoes autoactivation to
acquire its full proteolytic activity.30 Epithelial and carci-
noma cells activate matriptase in response to mild acidity
and CoCl2, a hypoxia-mimicking agent. A consequence ofajp.amjpathol.org - The American Journal of Pathology
Matriptase in B-Cell Lymphomathis unique feature of matriptase zymogen activation is that
matriptase is likely active in solid tumors, in which hypoxia is
common and results in an acidic milieu. Although both
hypoxia and its resultant extracellular acidosis are not
thought to be as important to the progression of B-cell
lymphoma as in carcinoma, this unique feature of matriptase
activation allowed us to demonstrate that neoplastic B cells
are able to generate and shed active matriptase with pro-
longed life span, because of the lack, or limited expression, of
HAI-1 or other matriptase inhibitors in NHL cells. This is in
a stark contrast to carcinoma cells, in which most active
matriptase is rapidly inhibited by high levels of HAI-1 and is
likely, therefore, to only activate and process those down-
stream substrates that are close to matriptase in the secretory
pathway and on the surface of the cells. The lack of large
amounts of HAI-1 means that activity of the matriptase will
only be inhibited when it encounters other canonical
matriptase inhibitors in the extracellular environment, such
as antithrombin, a-1 antiprotease, and a-2 antiplasmin.18
The presence of this potent active protease in the tumor
microenvironment of NHLs raises the distinct possibility
that the disease pathological characteristics are inﬂuenced
by processes such as matriptase-initiated proteolytic
cascades, altered ECM remodeling, and modulation of the
function of growth factors, cytokines, and chemokines. The
area over which the active matriptase may exert an effect is
also probably greater than in epithelial systems, with the
result that the stromal components of the tumor are also
exposed to the inﬂuence of free active matriptase. The shed
active matriptase in the extracellular milieu can, therefore,
initiate pericellular proteolysis by activating uPA in those
cells that express uPAR. Because uPAR is abundantly
expressed by stromal cells, including macrophages, ﬁbro-
blasts, and endothelial cells, but not by lymphoma cells,31
the matriptase-accelerated activation of the uPA/plasmin
system in NHL provides an important mechanism for cancer
cells to regulate pericellular proteolysis in stromal cells.
Among the potential downstream events resulting from
the presence of active matriptase, the activation of pro-HGF
has the potential to have a profound impact on B-cell
lymphomas. HGF, through engagement with its membrane
receptor, c-MET, promotes adhesion of lymphoma cells to
ECM molecules through the activation of integrins, an
important step for the invasion and dissemination of
lymphoma cells.32 In human B-cell lymphomas, HGF is
mainly produced by macrophages in the stromal compo-
nents of the tumor, and in the context of DLBCLs (eg,
approximately one third of tumors express c-MET). HGF is
secreted as a single-chain, inactive precursor, and is
mainly deposited in the ECM or on nearby cell surfaces.33
The extracellular activation of HGF is the principle switch
regulating HGF activity, and the activation of HGF may,
therefore, occur in the close vicinity of its target cells.
Several unrelated serine proteases have been reported
to be involved in the activation of HGF/scatter factor
(SF), including the blood coagulation factor XIIa, HGFThe American Journal of Pathology - ajp.amjpathol.orgactivator (HGFA), uPA, tissue plasminogen activator, and
matriptase.34e36 Although HGFA was reported to be the
most potent activator and is expressed by DLBCL and
multiple myeloma in vitro and in vivo, HGFA must itself
be activated by another protease to activate HGF; thus, it
apparently depends on the presence of another protease,
such as thrombin, at least in the in vitro setting.28,37 Among
the serine protease activators of pro-HGF, matriptase is
unique in the following ways: i) its potency is similar to
that of HGFA38; ii) it is co-expressed and colocalized with
the c-MET receptor at the basolateral plasma membrane in
the target epithelial, carcinoma,39 and some neoplastic B
cells; and iii) it has the ability to autoactivate, with the
result that active matriptase can be generated without
dependence on other proteases.30
In addition to serving as an important mediator that
facilitates the cross talk between neoplastic B cells and their
microenvironment, matriptase may also affect the cancer
cells (Figures 6 and 7). Induced expression of the matriptase
inhibitor, HAI-1, reduced BL cell proliferation, and reduced
matriptase expression resulting from shRNA knockdown
produced a decrease in the in vitro and in vivo proliferation
and colony-forming ability of BL and DLBCL cells. The
degree by which matriptase expression is suppressed seems
to be important to the nature of the altered behaviors of the
cancer cells. Previously, the loss of skin barrier function and
neonatal death in matriptase knockout mice can be rescued
by the re-expression of as little as 1% of wild-type matrip-
tase levels.40 This suggests that low levels of matriptase are
sufﬁcient to maintain its physiological functions. An
increase in the level of matriptase activation, combined with
the prolonged survival of active matriptase, provides
a plausible mechanism for cells with moderate suppression
of matriptase expression to compensate for the reduced
matriptase expression, allowing the maintenance of the
parental phenotype.
Given the role of matriptase in the modulation of the
tumor microenvironment and in the promotion of tumor
growth, the expression of matriptase may confer a malignant
advantage to matriptase-positive NHL and may, therefore,
have clinical implications for disease progression and
outcome. This hypothesis is supported by the fact that
matriptase was 1 of 76 genes identiﬁed in a 6912-gene array
that can distinguish activated B-cell (ABC)-like from
germinal center B-cellelike DLBCL.8 In this study, high
matriptase expression was detected in the DLBCL ABC-like
OCI-LY10 cells and not in FLs. It will be interesting in the
future studies to correlate matriptase expression with the
ABC subtype of DLBCL and determine whether matriptase-
expressing NHLs have worse overall survival than the
matriptase-negative counterparts.
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